News | EP Lab | July 31, 2019

Cardiac Device Complications Vary Widely Among Hospitals

Study out of Australia and New Zealand suggests better reporting, more quality improvement initiatives needed

Cardiac Device Complications Vary Widely Among Hospitals

July 31, 2019 — The chances of patients experiencing complications after having a cardiac device implanted vary according to where they have the procedure.

A study of 174 hospitals in Australia and New Zealand published in the Annals of Internal Medicine shows that the quality of care people receive may account for the wide variation in the rate of complications after having a cardiovascular implantable electronic device (CIED) insertion.

“The study included 81,304 patients who received a new CIED with 65,711 permanent pacemakers and 15,593 implantable cardioverter-defibrillators,” said the study’s lead author, University of Adelaide’s Isuru Ranasinghe, Ph.D., senior cardiologist, Central Adelaide Local Health Network. “Permanent pacemakers and implantable cardioverter-defibrillators are among the most common and costly devices implanted in hospitals.

“CIED complications are common with 8.2 percent of patients implanted with new devices having a major device-related complication within 90 days of their operation. Complications experienced by patients vary between two- and three-fold among hospitals, which suggests that there is significant variation in CIED care quality,” added Ranasinghe

Nearly 19,000 pacemakers and more than 4000 defibrillators were implanted in Australia alone last year. Pacemakers are often fitted to elderly people who suffer from bradycardia where their heart beats too slowly. They use electrical pulses to prompt the heart to beat at a normal rate. Cardioverter-defibrillators track a person’s heart rate, and if an abnormal heart rhythm is detected, the device delivers an electric shock to restore the heart rhythm to normal.

“Serious complications can cause considerable patient harm and adds to avoidable healthcare costs. About 60 percent of these complications occur after leaving the hospital so many doctors and hospitals may not be fully aware of the complications experienced by patients,” said Ranasinghe.

Associate Prof. Anand Ganesan, a study co-investigator and a cardiac electrophysiologist at Flinders Medical Centre said, “What this study really shows is that we should be routinely reporting hospital complication rates to make these fully visible to clinicians, hospitals and the community at large. We should also invest in strategies proven to reduce these, such as optimizing procedural technique, adopting better infection control measures and managing blood thinning drugs peri-procedure.”

Ranasinghe said, “Encouraging hospitals to take part in quality improvement activities such as auditing complications and engaging in clinical quality registries also reduce complications over time.”

This study was funded by the HCF Research Foundation, with additional funding support from the National Heart Foundation of Australia and The Hospital Research Foundation.

For more information: www.annals.org

 

Reference

1. Ranasinghe I., Labrosciano C., Horton D., et al. Institutional Variation in Quality of Cardiovascular Implantable Electronic Device Implantation: A Cohort Study. Annals of Internal Medicine, published online July 30, 2019. DOI: 10.7326/M18-2810

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init